This week’s major U.S. developments include FDA’s requirement for a vitamin B6 deficiency and seizure warning on carbidopa/levodopa products and the agency’s request to remove suicidal ideation and behavior language from certain GLP-1 RA labels after finding no increased risk.
On the European side, EMA’s latest PRAC visibility continues through its March meeting materials and committee pages, reinforcing how regularly signal discussions and pharmacovigilance outputs are published into the public domain.
The combined picture is clear: the safety conversation this week was not one-directional. One FDA action added a warning. Another removed one. That contrast is a useful reminder that pharmacovigilance is driven by evolving evidence, not a permanent ratchet toward ever-longer labels. That final point is an inference from the week’s developments.
0 Comments